Curanex Pharmaceuticals Inc Additional Paid in Capital, Common Stock
Curanex Pharmaceuticals Inc (CURX) had Additional Paid in Capital, Common Stock of $16.07 million as of 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:AdditionalPaidInCapitalCommonStock · last filed 2026-08-14
- 2026-06-30: Additional Paid in Capital, Common Stock $16.07M.
- 2026-03-31: Additional Paid in Capital, Common Stock $16.07M.
- 2025-12-31: Additional Paid in Capital, Common Stock $16.06M.
- 2025-09-30: Additional Paid in Capital, Common Stock $16.06M.
| Period end | Additional Paid in Capital, Common Stock |
|---|---|
| 2026-06-30 | $16.07M 10-Q · filed 2026-08-14 |
| 2026-03-31 | $16.07M 10-Q · filed 2026-05-14 |
| 2025-12-31 | $16.06M 10-Q · filed 2026-08-14 |
| 2025-09-30 | $16.06M 10-Q · filed 2025-11-17 |
| 2025-06-30 | $923.31K 10-Q · filed 2025-09-09 |
| 2024-12-31 | $923.31K 10-K · filed 2026-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |